Amyloidosis: past, present and visions for the future
We look back on an eventful time: the introduction and approval of new drugs for different types of amyloidosis have changed the prognosis of our patients for the better over the last decade.
Grosser Hörsaal PATH D 22
Universitätsspital Zürich
Schmelzbergstrasse 12
8091 Zürich
07.09.2023
1.15 pm - 6.15 pm
2 SGPATH, 3 SGH, SGMO, SGN, SGK, SNG, SGUM, 4 SGAIM
| 1.15 pm | Opening Ceremony/Music B. Gerber, EOC; A. Flammer, USZ; R. Schwotzer, USZ |
|---|---|
| 1.45 pm | History of amyloidosis – an overview and greetings from the president of the International Society of Amyloidosis (ISA) S. Schönland, Universitätsklinikum Heidelberg D |
| 2.15 pm | Research of protein folding disease – what do we need to know as clinicians A. Aguzzi, USZ |
| 2.45 pm | Why do we need amyloidosis centers – the role of a center of excellence G. Palladini, Fondazione IRCCS Policlinico San Matteo Pavia I |
| 3.15 pm | State of the art lectures Variant transthyretin amyloidosis (ATTRv) K. Hahn, Charité Berlin D |
| 3.35 pm | Coffee Break/Music
Chair: U. Hegenbart, Universitätsklinikum Heidelberg D; H. Seeger, KSB |
| 4.15 pm | Wild-type transthyretin amyloidosis (ATTRwt) G. Pölzl, Universitätsklinikum Innsbruck A |
| 4.45 pm | Lightchain (AL) amyloidosis M. Gertz, Mayoclinic Rochester USA |
| 5.15 pm | Discussing challenging cases from the network with the experts Gerber, EOC; A. Flammer, USZ, R. Schwotzer, USZ |
| 5.45 pm | Amyloidosis Network Zurich – past, present and visions for the future R. Schwotzer, USZ; A. Flammer, USZ |
| 6.15 pm | Apéro |